{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:17:18Z","timestamp":1775801838768,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40259-017-0212-y","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:58:58Z","timestamp":1487926738000},"page":"125-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid"],"prefix":"10.1007","volume":"31","author":[{"given":"Kai Uwe","family":"Radomski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lattner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"R\u00f6misch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"issue":"Suppl 15","key":"212_CR1","first-page":"3","volume":"14","author":"JM Dwyer","year":"1996","unstructured":"Dwyer JM. Immunoglobulins in autoimmunity: history and mechanisms of action. Clin Exp Rheumatol. 1996;14(Suppl 15):3\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"212_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1542\/pir.16-11-403","volume":"16","author":"S Ramesh","year":"1995","unstructured":"Ramesh S, Schwartz SA. Therapeutic uses of intravenous immunoglobulin (IVIG) in children. Pediatr Rev. 1995;16:403\u201310.","journal-title":"Pediatr Rev"},{"key":"212_CR3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00006454-199707000-00012","volume":"16","author":"ER Stiehm","year":"1997","unstructured":"Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997;16:696\u2013707.","journal-title":"Pediatr Infect Dis J"},{"key":"212_CR4","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"212_CR5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.molimm.2004.07.046","volume":"42","author":"R Lemieux","year":"2005","unstructured":"Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005;42:839\u201348.","journal-title":"Mol Immunol"},{"issue":"Suppl 1","key":"212_CR6","first-page":"11","volume":"97","author":"M Haeney","year":"1994","unstructured":"Haeney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol. 1994;97(Suppl 1):11\u20135.","journal-title":"Clin Exp Immunol"},{"key":"212_CR7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1331\/108658002763316888","volume":"42","author":"M Ballow","year":"2002","unstructured":"Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc. 2002;42:449\u201358.","journal-title":"J Am Pharm Assoc"},{"key":"212_CR8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","volume":"14","author":"T Burnouf","year":"2000","unstructured":"Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 2000;14:94\u2013110.","journal-title":"Blood Rev"},{"key":"212_CR9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/157488607779315480","volume":"2","author":"J Carbone","year":"2007","unstructured":"Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf. 2007;2:9\u201318.","journal-title":"Curr Drug Saf"},{"key":"212_CR10","unstructured":"World Health Organization. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report Series No. 924, Annex 4. Geneva: World Health Organization; 2004."},{"key":"212_CR11","unstructured":"European Medicines Agency. Guideline on plasma-derived medicinal products. EMA\/CHMP\/BWP\/706271\/2010. London: European Medicines Agency; 2011. p. 33."},{"key":"212_CR12","unstructured":"European Medicines Agency. CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMA\/CHMP\/BWP\/303353\/2010. London: European Medicines Agency; 2011. p. 26."},{"key":"212_CR13","unstructured":"Bundesgesundheitsamt und Paul-Ehrlich-Institut. Bekanntmachung \u00fcber die Zulassung von Arzneimittel. Anforderungen an Validierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma. Berlin, 20. Dezember 1993\/Langen, 21. Januar 1994; BAnz; 1994. p. 4742\u201344."},{"key":"212_CR14","unstructured":"European Committee for Proprietary Medicinal Products (CPMP). European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit: note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP\/BWP\/268\/95. London: European Medicines Agency; 1996. p. 14."},{"key":"212_CR15","unstructured":"European Medicines Agency. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to VCJD risk. CPMP\/BWP\/CPMP\/5136\/03. London: European Medicines Agency; 2004. p. 33."},{"key":"212_CR16","unstructured":"World Health Organization. Recommendations for the production, control and regulation of human plasma for fractionation. World Health Organization technical report series no. 941. Geneva: World Health Organization; 2007. pp. 189\u2013264."},{"key":"212_CR17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/trf.13279","volume":"56","author":"M Oshita","year":"2016","unstructured":"Oshita M, Yokoyama T, Takei Y, Takeuchi A, Ironside JW, Kitamoto T, et al. Efficient propagation of variant Creutzfeldt\u2013Jakob disease prion protein using the cell-protein misfolding cyclic amplification technique with samples containing plasma and heparin. Transfusion. 2016;56:223\u201330.","journal-title":"Transfusion"},{"key":"212_CR18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10875-007-9107-x","volume":"27","author":"M Berger","year":"2007","unstructured":"Berger M. Flebogamma, 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628\u201333.","journal-title":"J Clin Immunol"},{"key":"212_CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1423-0410.1996.tb01334.x","volume":"70","author":"T Burnouf","year":"1996","unstructured":"Burnouf T. Value of virus filtration as a method for improving the safety of plasma products. Vox Sang. 1996;70:235\u20136.","journal-title":"Vox Sang"},{"key":"212_CR20","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/j.1537-2995.2009.02222.x","volume":"49","author":"HO Dichtelm\u00fcller","year":"2009","unstructured":"Dichtelm\u00fcller HO, Biesert L, Fabbrizzi F, Gajardo R, Groner A, von Hoegen I, et al. Robustness of solvent\/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion. 2009;49:1931\u201343.","journal-title":"Transfusion"},{"key":"212_CR21","first-page":"23","volume-title":"Virus inactivation in plasma products","author":"N Heimburger","year":"1989","unstructured":"Heimburger N, Karges HE. Strategies to produce virus-safe blood derivatives. In: Morgenthaler J-J, editor. Virus inactivation in plasma products. Basel: Karger; 1989. p. 23\u201333."},{"key":"212_CR22","first-page":"407","volume":"182","author":"D Menache","year":"1985","unstructured":"Menache D, Aronson DL. Measures to inactivate viral contaminants of pooled plasma products. Prog Clin Biol Res. 1985;182:407\u201323.","journal-title":"Prog Clin Biol Res"},{"key":"212_CR23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/9781118356807.ch13","volume-title":"Production of plasma proteins for therapeutic use","author":"A Buchacher","year":"2013","unstructured":"Buchacher A, Kaar W. Intravenous immunoglobulin G from human plasma\u2014purification concepts and important quality criteria. In: Bertolini J, Goss N, Curling J, editors. Production of plasma proteins for therapeutic use. Hoboken: Wiley; 2013. p. 185\u2013206."},{"key":"212_CR24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1423-0410.2007.01016.x","volume":"94","author":"G Poelsler","year":"2008","unstructured":"Poelsler G, Berting A, Kindermann J, Spruth M, Hammerle T, Teschner W, et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang. 2008;94:184\u201392.","journal-title":"Vox Sang"},{"key":"212_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","volume":"84","author":"W Lebing","year":"2003","unstructured":"Lebing W, Remington KM, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang. 2003;84:193\u2013201.","journal-title":"Vox Sang"},{"key":"212_CR26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/biol.2002.0334","volume":"30","author":"M Korneyeva","year":"2002","unstructured":"Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR Jr. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals. 2002;30:153\u201362.","journal-title":"Biologicals"},{"key":"212_CR27","doi-asserted-by":"crossref","unstructured":"Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin. 2008;28:765\u201378, viii.","DOI":"10.1016\/j.iac.2008.06.002"},{"key":"212_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biologicals.2006.01.002","volume":"35","author":"C Kempf","year":"2007","unstructured":"Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals. 2007;35:35\u201342.","journal-title":"Biologicals"},{"key":"212_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","volume":"98","author":"M Radosevich","year":"2010","unstructured":"Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010;98:12\u201328.","journal-title":"Vox Sang"},{"key":"212_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biologicals.2016.10.003","volume":"45","author":"C Mersich","year":"2017","unstructured":"Mersich C, Ahrer K, Buchacher A, Ernegger T, Kohla G, Kannicht C, et al. Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga\u00ae). Biologicals. 2017;45:33\u20138. doi: 10.1016\/j.biologicals.2016.10.003 .","journal-title":"Biologicals"},{"key":"212_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biologicals.2013.10.003","volume":"42","author":"S Caballero","year":"2014","unstructured":"Caballero S, Diez JM, Belda FJ, Otegui M, Herring S, Roth NJ, et al. Robustness of nanofiltration for increasing the viral safety margin of biological products. Biologicals. 2014;42:79\u201385.","journal-title":"Biologicals"},{"key":"212_CR32","doi-asserted-by":"crossref","unstructured":"Hongo-Hirasaki T. Optimization of virus removal filtration processes. Presentation at PDA virus & TSE safety forum, Lisbon, 2015. In: Willkommen H, Bl\u00fcmel J, Brorson K, Chen D, Chen Q, Gr\u00f6ner A, et al. Meeting report: 2015 PDA virus & TSE safety forum. PDA J Pharm Sci Technol. 2016;70(2):177\u201388.","DOI":"10.5731\/pdajpst.2016.006569"},{"key":"212_CR33","volume-title":"Grundzuge Biologisch-medizinischer Statistik","author":"Cavalli-Sforza L Biometrie","year":"1974","unstructured":"Biometrie Cavalli-Sforza L. Grundzuge Biologisch-medizinischer Statistik. 4th ed. Stuttgart: Gustav Fischer; 1974.","edition":"4"},{"key":"212_CR34","volume-title":"Bacteriological analytical manual. Appendix 2: most probable number from serial dilutions","author":"R Blodgett","year":"2010","unstructured":"Blodgett R. Bacteriological analytical manual. Appendix 2: most probable number from serial dilutions. Silver Spring: US Food and Drug Administration; 2010."},{"key":"212_CR35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2307\/3001491","volume":"6","author":"WG Cochran","year":"1950","unstructured":"Cochran WG. Estimation of bacterial densities by means of the \u201cmost probable number\u201d. Biometrics. 1950;6:105\u201316.","journal-title":"Biometrics"},{"key":"212_CR36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1128\/JCM.32.3.732-739.1994","volume":"32","author":"LE Myers","year":"1994","unstructured":"Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol. 1994;32:732\u20139.","journal-title":"J Clin Microbiol"},{"key":"212_CR37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biologicals.2011.06.007","volume":"39","author":"C Brownie","year":"2011","unstructured":"Brownie C, Statt J, Bauman P, Buczynski G, Skjolaas K, Lee D, et al. Estimating viral titres in solutions with low viral loads. Biologicals. 2011;39:224\u201330.","journal-title":"Biologicals"},{"key":"212_CR38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-0934(99)00135-4","volume":"84","author":"DC Lee","year":"2000","unstructured":"Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods. 2000;84:77\u201389.","journal-title":"J Virol Methods"},{"key":"212_CR39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood.V90.3.1309","volume":"90","author":"G Rossi","year":"1997","unstructured":"Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood. 1997;90:1309\u201314.","journal-title":"Blood"},{"key":"212_CR40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tmrv.2013.05.002","volume":"27","author":"KJ Velthove","year":"2013","unstructured":"Velthove KJ, Over J, Abbink K, Janssen MP. Viral safety of human plasma-derived medicinal products: impact of regulation requirements. Transfus Med Rev. 2013;27:179\u201383.","journal-title":"Transfus Med Rev"},{"key":"212_CR41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.biologicals.2010.02.008","volume":"38","author":"S Caballero","year":"2010","unstructured":"Caballero S, Nieto S, Gajardo R, Jorquera JI. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin. Biologicals. 2010;38:486\u201393.","journal-title":"Biologicals"},{"key":"212_CR42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biologicals.2012.04.007","volume":"40","author":"PL Roberts","year":"2012","unstructured":"Roberts PL, Dunkerley C, Walker C. Virus reduction in an intravenous immunoglobulin by solvent\/detergent treatment, ion-exchange chromatography and terminal low pH incubation. Biologicals. 2012;40:345\u201352.","journal-title":"Biologicals"},{"key":"212_CR43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1423-0410.2005.00710.x","volume":"90","author":"FG Terpstra","year":"2006","unstructured":"Terpstra FG, Parkkinen J, Tolo H, Koenderman AH, Ter Hart HG, von Bonsdorff L, et al. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang. 2006;90:21\u201332.","journal-title":"Vox Sang"},{"key":"212_CR44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1423-0410.2003.00265.x","volume":"84","author":"T Burnouf","year":"2003","unstructured":"Burnouf T, Radosevich M, El-Ekiaby M, Satoh S, Sato T, Amin SN, et al. Nanofiltration of single plasma donations: feasibility study. Vox Sang. 2003;84:111\u20139.","journal-title":"Vox Sang"},{"key":"212_CR45","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.biologicals.2010.08.003","volume":"38","author":"JM Diez","year":"2010","unstructured":"Diez JM, Caballero S, Belda F, Otegui M, Gajardo R, Jorquera JI. Capacity of the manufacturing process of Flebogamma\u00ae DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent. Biologicals. 2010;38:670\u20134.","journal-title":"Biologicals"},{"key":"212_CR46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/biot.200500037","volume":"1","author":"A Buchacher","year":"2006","unstructured":"Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma\u2014aspects of yield and virus safety. Biotechnol J. 2006;1:148\u201363.","journal-title":"Biotechnol J"},{"issue":"Suppl 4","key":"212_CR47","first-page":"132","volume":"11","author":"V Angelis De","year":"2013","unstructured":"De Angelis V, Breda A. Plasma-derived medicinal products self-sufficiency from national plasma: to what extent? Blood Transfus. 2013;11(Suppl 4):132\u20137.","journal-title":"Blood Transfus"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0212-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0212-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0212-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T17:32:42Z","timestamp":1719077562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0212-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0212-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]}}}